Benefit–Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
Sign Up to like & getrecommendations! Published in 2018 at "Drug Safety"
DOI: 10.1007/s40264-018-0760-1
Abstract: Blinatumomab is the first-and-only Food and Drug Administration (FDA)-approved cluster of differentiation (CD) 19-directed CD3 bispecific T-cell engager (BiTE®) immunotherapy. It is currently FDA approved for the treatment of adults and children with Philadelphia chromosome-positive… read more here.
Keywords: relapsed refractory; blinatumomab treatment; cell precursor; refractory cell ... See more keywords